

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: PTI-001CN

APPLICANT: Kornblith

SERIAL NO.: 09/040,161

FILING DATE: March 17, 1998 GROUP: 1651

U.S. PATENT DOCUMENTS CLASS SUB FILING DATE IF NAME DOCUMENT DATE EXAM. CLASS APPROPRIATE NUMBER INIT. 12-27-1983 Stampfer et al. 4,423,145 ΑI 170 Thornthwaite 4,668,618 05-26-1987 A2 4,937,187 05-26-1990 Rotman A3 Weisenthal A4 4,996,145 02-26-1991 A5 5,242,806 09-07-1993 Yen-Maguire et al. 5,270,172 12-14-1993 Morgan A6 Naughton et al. A7 5,443,950 08-22-1995 03-04-1997 Eriksson et al. 5,607,918 A8 03-17-1998 Kornblith 5,728,541 Α9 Knowles et al. 08-04-1998 5,789,158 A10 02-23-1999 Drolet et al. 5,874,218 All 5,888,765 03-30-1999 Patterson et al. A12 5,942,385 08-24-1999 Hirth A13 **Parandoosh** A14 5,972,639 10-26-1999 Fruehauf et al. A15 12-28-1999 6,008,007 6,020,473 02-01-2000 Keyt et al. AIG 6,261,795 07-17-2001 Fruchauf et al. A17 6,303,324 10-16-2001 Fruehauf et al. A18 6,335,170 01-01-2002 Orntoft A19 Kornblith A20 6,416,967 07-09-2002 01-28-2003 Fruehauf et al. A21 6,511,806 05-22-2003 Fruehauf et al. 2003/0096290 A1 A22 ROITDINER DATE CONSIDERED **EXAMINER**



FORM PTO - 1449

ATTORNEY DOCKET NO.: PTI-001CN

INFORMATION DISCLOSURE STATEMENT

APPLICANT: Kornblith

INFOR	NFORMATION DISCLOSURE STATEMENT		AENT	APPLICANT: Kornbitti					
				SERIAL NO.: 09/040,161					
					FILING I	DATE: M	larch 17,	1998 GRO	JP: 1651
	=		FORE	GN PATEN	T DOCU	IMENTS			
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG
120	ВІ	WO 96/10742	04-11-1996	wo					
			OTHER A	RT, JOURN	AL ART	ICLES, E	TC.		
EXAM. INIT.	отн	ER DOCUMENT	'S: (Including	Author, Title	, Date, Rele	evant Page:	s, Place of I	Publication)	
To	CI	Alley, M., et al. Sensitivity in Se							h and Drug
	C2	Andreotti, P., et Tumour Cell Li 373-378 (1994)	nes and Clinica						
	C3	Arnold, J., et al., "Evaluation of Chemopreventative Agents in Different Mechanistic Classes Using a Rat Tracheal Epithelial Cell Culture Transformation Assay," Cancer Research, vol. 55, pp. 537-543 (1995).							
	C4	Bosanquet, A., "Short-term <i>In Vitro</i> Drug Sensitivity Tests For Cancer Chemotherapy. A Summary of Correlations of Test Result With Both Patient Response and Survival," FORUM 4.2, pp. 179-195 (1994).							
	C5	Broadley, C., et al., "A Tissue-Culture Model for the Study of Canine Vocal Fold Fibroblasts," Laryngoscope, vol. 105, no. 1, pp. 23-27 (1995).							
	C6	Burczynski, M., et al., "Toxicogenomics-Based Discrimination of Toxic Mechanism in HepG2 Human Hepatoma Cells," Toxicological Sciences, vol. 58, no.2, pp. 399-415 (2000).							
,	C7	Cilley, R., et al., "Fetal Lung Development: Airway Pressure Enhances the Expression of Developmental Genes," Journal of Pediatric Surgery, vol. 35, no. 1, pp. 113-119 (2000).							
	C8	Dietel, M., et al., "In Vitro Prediction of Cytostatic Drug Resistance in Primary Cell Cultures of Solid Malignant Turnours," Eur. J. Cancer, vol. 29A, no. 3, pp. 416-420 (1993).							
	C9	Dudley, D., et al., "A Human Endometrial Explant System: Validation and Potential Applications," Am. J. Obstet. Gynecol., vol. 167, no. 6, pp. 1774-1780 (1992).							
	C10	Fruehauf, J., "In Vitro Assay-assisted Treatment Selection For Women With Breast or Ovarian Cancer," Endocrine-Related Cancer, vol. 9, pp. 171-182 (2002).							
	CH	Frykholm, G., et al., "Heterogeneity in Antigenic Expression and Radiosensitivity in Human Colon Carcinoma Cell Lines," In Vitro Cell Dev. Biol., vol. 27A, pp. 900-906 (1991).							
(CI2	Fulda, S., et al., Cancer, vol. 31			of Cytostati	c Drugs on	Neuroblast	oma Cells <i>In Vi</i>	tro," Eur. J.
EXAMIN	ER	R. GITO	omen		DATE CO	NSIDERE	D 6	///64,	

		FEB TOADEWARD	The state of the s		
FORM PTO - 1449			ATTORNEY DOCKET NO.: PTI-001CN		
INFOR	MATIO	ON DISCLOSURE STATEMENT	APPLICANT: Kornblith		
			SERIAL NO.: 09/040,161		
		·	FILING DATE: March 17, 1998 GROUP: 1651		
176	C13	Gamboa, G., et al., "Characterization and I Cell Line," Gynccologic Oncology, vol. 58	Development of UCI 107, a Primary Human Ovarian Carcinoma 6, pp. 336-343 (1995).		
	C14	Gerweck, et al., "Radiation Sensitivity of C pp. 231-234 (1977).	Cultured Human Glioblastoma Cells," Radiology, vol. 125, no. 1		
	CIS	Ghosh, A., et al., "Immunohistological Staining of Reactive Mesothelium, Mesothelium, and Lun Carcinoma with a Panel of Monoclonal Antibodies," J. Clin. Pathol., vol. 40, pp 19-25 (1987).			
	C16		ng Procedures, and Design of Cell Proliferation Studies Relating to rspectives, vol. 101, supp. 5, pp. 59-66 (1993).		
	CI7	Gress, T., et al., "Development of a Database on Transcribed Sequences in Tumour Cells and Identification of Changes in Transcription Patterns Related to Transformation and Other Tumour Cell Properties for the Global Finger Printing Analysis of Human Pancreatic Carcinoma cDNA Libraries," Biomedi. Health Revol. 24, pp. 171-181 (1998).			
	C18	Hoffman, R., "The Three-Dimensional Question: Can Clinically Relevant Tumor Drug Resistance be Measured In Vitro?" Cancer and Metastasis Reviews, vol. 13, no. 2, pp. 169-173 (1994).			
	C19	Kaaijk, P., et al., "Daunorubicin and Doxorubicin but not BCNU have Deleterious Effects on Organo Multicellular Spheroids of Gliomas," British Journal of Cancer, vol. 74, no. 2, pp. 187-193 (1996).			
	C20	Kitamura, M., et al., "Chemosensitivty of Gastric Cancer Using Adhesive Tumor Cell Culture Syst Oncology Reports, vol. 2, no. 1, pp. 27-31 (1995).			
	C21	Komblith, P., "Role of Tissue Culture in Prediction of Malignancy," Clinical Neurosurgery, vo. 376 (1978).			
	C22	Kornblith, P., et al., "Variations in Response of Human Brain Tumors to BCNU In Vitro," Journal of Neurosurgery, vol. 48, no. 4, pp. 580-586 (1978).			
	C23	Kruczynski, A., et al., "Evidence of a Direct Relationship Between the Increase in the In Vitro Passage Number of Human Non-Small-Cell-Lung Cancer Primocultures and their Chemosensitivity," Anticance Research, vol. 13, pp. 507-514 (1993).			
	C24	McGuire, W., et al., "In vitro assays to Pre Breast Cancer Research and Treatment, vol	dict Drug Sensitivity and Drug Resistance, A Panel Discussion," I. 12, pp. 7-21 (1988).		
	C25	Nance, K., et al., "Immunocytochemical P Effusions," Am. J. Clin. Pathol., vol. 95, pp	anel for the Identification of Malignant Cells in Scrous p. 867-874 (1991).		
	C26	Persons, D., et al., "Interphase Molecular C American Journal of Pathology, vol. 142, n	Cytogenetic Analysis of Epithelial Ovarian Carcinomas," no. 3, pp. 733-741 (1993).		
V	C27		rity of Keratin Proteins in Formalin-Fixed, Paraffin-Embedded		

Tissue Requires Preliminary Trypsinization," Journal of Histochemistry and Cytochemistry, vol. 33, no. 5,

DATE CONSIDERED

pp. 465-473 (1985).

EXAMINER

RGITORICA

		The state of the s			
FORM PTO - 1449			ATTORNEY DOCKET NO.: PTI-001CN		
INFOR	MATIC	ON DISCLOSURE STATEMENT	APPLICANT: Kornblith SERIAL NO.: 09/040,161		
			FILING DATE: March 17, 1998 GROUP: 1651		
Ro	C28		stochemical Evidence of Squamous Metaplasia from the thology, vol. 17, no. 3, pp. 272-275 (1990).		
1	C29	Robert, J., "Chemosensitivity Testing. Prediction of Response to Anticancer Drugs Using In Vitro Assay Electronic Journal of Oncology, vol. 2, pp. 198-210 (1999).			
	C30	Singh, H., et al., "Significance of Epithelial Membrane Antigen in the Work-Up of Problematic Serous Effusions," Diagnostic Cytopathology, vol. 13, no. 1, pp. 3-7 (1995).			
	C31	Stephens, S., et al., "A Longitudinal Study of γ-Interferon Production by Peripheral Blood Mononuclear Cells from Breast- and Bottle-Fed Infants," Clin. Exp. Immunol., vol. 65, pp. 396-400 (1986).			
	C32	Stewart, R., et al., "Glutamate Accumulation By Human Gliomas and Meningiomas in Tissue Culture," Brain Research, vol. 118, no. 3, pp. 441-452 (1976).			
	C33	Stoop, J., et al., "Identification of Malignant Cells in Scrous Effusions Using a Panel of Monoclonal Antibodies Ber-EP4, MCA-b-12 and EMA," Cytopathology, vol. 3, pp. 297-302 (1992).			
	C34	Wiseman, I., "A Modification of Hepatest, using the Terasaki Plate, for the Detection of Hb ₂ Ag in Blood Donors," J. Clin. Pathol., vol. 29, no. 3, pp. 264-266 (1976).			
	C35	International Search Report for PCT/US01/32540 dated April 18, 2002.			
	C36 International Search Report for PCT/US97/11595 dated August 17, 1998.				
C37 International Search Report for EP 97 93 3267 dated May 3, 2002.					
EXAMIN	EXAMINER RECTOMEN DATE CONSIDERED 6/104				

FEB 1 5 2003
TECH CENTER 1600/2900 ATTORNEY DOCKET NO.: PTI-001CN FORM-PTO - 1449 **QN DISCLOSURE STATEMENT** APPLICANT: Kornblith SERIAL NO.: 09/040,161 FILING DATE: March 17, 1998 **U.S. PATENT DOCUMENTS** SUB EXAM. DOCUMENT FILING DATE IF DATE NAME **CLASS** INIT. NUMBER **CLASS** APPROPRIATE 4,423,145 12-27-1983 Stampfer et al. 435 32 RG A2 4,668,618 05-26-1987 Thornthwaite 435 6 4,937,187 05-26-1990 435 30 A3 Rotman 5,242,806 09-07-1993 435 32 **A4** Yen-Maguire et al. 29 **A5** 5,270,172 12-14-1993 Morgan 435 A6 5,443,950 08-22-1995 Naughton et al. 435 1 Α7 5,607,918 03-04-1997 Eriksson et al. 514 12 435 29 5,728,541 03-17-1998 A8 Kornblith Sö Knowles et al. 435 Α9 5,789,158 08-04-1998 6 5,874,218 02-23-1999 Drolet et al. 435 A10 5,888,765 03-30-1999 Patterson et al. 435 69.1 5,942,385 08-24-1999 Hirth 435 4 A12 Z A C P 5,972,639 10-26-1999 Parandoosh 435 29 A13 6,020,473 536 23.1 A14 02-01-2000 Keyt et al. A15 6,335,170 01-01-2002 Orntoft 435 6 A16 6,416,967 07-09-2002 Kornblith 435 29 FOREIGN PATENT DOCUMENTS EXAM. DOCUMENT DATE COUNTRY **CLASS FILING ABSTRACT ENGLISH** INIT. NUMBER CODE CLASS DATE ONLY LANG 76 ВI WO 96/10742 04-11-1996 wo OTHER ART, JOURNAL ARTICLES, ETC. EXAM. OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) INIT. Alley, M., "Morphometric and Colorimetric Analyses of Human Tumor Cell Line Growth and Drug 16 Sensitivity in Soft Agar Culture," Cancer Research, vol. 51, pp. 1247-1256 (1991). 12/13/04 RGITOMER **EXAMINER** DATE CONSIDERED

(4 -	125 m
(KB)	3 The state of the
Zen.	n E

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: PTI-001CN

APPLICANT: Kornblith

SERIAL NO.: 09/040,161

1651

		/65/	
		FILING DATE: March 17, 1998 GROUP: 1623	
EXAM. INIT.	ОТНЕ	ER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
26	C2	Andreotti, P., "TCA-100 Tumour Chemosensitivity Assay: Differences in Sensitivity between Cultured Tumour Cell Lines and Clinical Studies," J Biolumin Chemilumin, vol. 9, pp. 373-378 (1994).	
1	C3	Broadley, C., et al., "A Tissue-Culture Model for the Study of Canine Vocal Fold Fibroblasts," Laryngoscope, vol. 105, no. 1, pp. 23-27 (1995).	
-	C4	Burczynski, M., et al., "Toxicogenomics-Based Discrimination of Toxic Mechanism in HepG2 Human Hepatoma Cells," Toxicological Sciences, vol. 58, no.2, pp. 399-415 (2000).	
	C5	Cilley, R., et al., "Fetal Lung Development: Airway Pressure Enhances the Expression of Developmental Genes," Journal of Pediatric Surgery, vol. 35, no. 1, pp. 113-119 (2000).	
	C6	Dietel, M., et al., "In Vitro Prediction of Cytostatic Drug Resistance in Primary Cell Cultures of Solid Malignant Tumours," Eur J Cancer, vol. 29A, no. 3, pp. 416-420 (1993).	
	C7	Dudley, D., et al., "A Human Endometrial Explant System: Validation and Potential Applications," Am J Obstet Gynecol, vol. 167, no.6, pp. 1774-1780 (1992).	
	C8 Frykholm, G., et al., "Heterogeneity in Antigenic Expression and Radiosensitivity in Human Carcinoma Cell Lines," In Vitro Cell Dev. Biol., vol. 27A, pp. 900-906 (1991).		
	C9	Fulda, S., et al., "Antiproliferative Potential of Cytostatic Drugs on Neuroblastoma Cells <i>In Vitro</i> ," Eur J o Cancer, vol. 31A, no. 4, pp. 616-621 (1995).	
	Gamboa, G., et al., "Characterization and Development of UCI 107, a Primary Human Ovarian Carcinoma Cell Line," Gynecologic Oncology, vol. 58, pp. 336-343 (1995).		
	CH	Ghosh, A., et al., "Immunohistological Staining of Reactive Mesothelium, Mesothelium, and Lung Carcinoma with a Panel of Monoclonal Antibodies," J Clin Pathol, vol. 40, pp 19-25 (1987).	
	C12	Goldsworthy, T., et al., "Concepts, Labeling Procedures, and Design of Cell Proliferation Studies Relating Carcinogenesis," Environmental Health Perspectives, vol. 101, supp. 5, pp. 59-66 (1993).	
of Changes in Transcription Patt		Gress, T., et al., "Development of a Database on Transcribed Sequences in Tumour Cells and Identification of Changes in Transcription Patterns Related to Transformation and Other Tumour Cell Properties for the Global Finger Printing Analysis of Human Pancreatic Carcinoma cDNA Libraries," Biomed I. Health Res., vol. 24, pp. 171-181 (1998).	
	C14	Hoffman, R., "The Three-Dimensional Question: Can Clinically Relevant Tumor Drug Resistance be Measured <i>In Vitro</i> ?" Cancer and Metastasis Reviews, vol. 13, no. 2, pp. 169-173 (1994).	
	C15	Kaaijk, P., et al., "Daunorubicin and Doxorubicin but not BCNU have Deleterious Effects on Organotypic Multicellular Spheroids of Gliomas," British Journal of Cancer, vol. 74, no. 2, pp. 187-193 (1996).	
V	C16 Kitamura, M., et al., "Chemosensitivty of Gastric Cancer Using Adhesive Tumor Cell Culture System," Oncology Reports, vol. 2, no. 1, pp. 27-31 (1995).		
EXAMIN	IER	ROLTONIEN DATE CONSIDERED /2/13/04	

INFORMATION DISCLOSURE STATEMENT

FORM PTO - 144

ATTORNEY DOCKET NO.: PTI-001CN

APPLICANT: Kornblith

SERIAL NO.: 09/040,161

GROUP: 1623 FILING DATE: March 17, 1998

		DING DATE: March 17, 1990 GROOT: 2023			
EXAM. OTH	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)				
Re C17	Kornblith, P., "Role of Tissue Culture in Predict 346-376 (1978).	tion of Malignancy," Clinical Neurosurgery, vol. 25, pp.			
C18	Kornblith, P., et al., "Variations in Response of Human Brain Tumors to BCNU In Vitro," Journal of Neurosurgery, vol. 48, no. 4, pp. 580-586 (1978).				
C19	Nance, K., et al., "Immunocytochemical Panel for the Identification of Malignant Cells in Serous Effusions," Am J Clin Pathol, vol. 95, pp. 867-874 (1991).				
C20	Persons, D., et al., "Interphase Molecular Cytogenetic Analysis of Epithelial Ovarian Carcinomas," American Journal of Pathology, vol. 142, no. 3, pp. 733-741 (1993).				
C21	Pinkus, G., et al., "Optimal Immunoreactivity of Keratin Proteins in Formalin-Fixed, Paraffin-Embedded Tissue Requires Preliminary Trypsinization," Journal of Histochemistry and Cytochemistry, vol. 33, no. 5, pp. 465-473 (1985).				
C22	Raju, G., "The Histological and Immunohistochemical Evidence of Squamous Metaplasia from the Myoepithelial Cells in the Breast," Histopathology, vol. 17, no. 3, pp. 272-275 (1990).				
C23	Singh, H., et al., "Significance of Epithelial Membrane Antigen in the Work-Up of Problematic Serous Effusions," Diagnostic Cytopathology, vol. 13, no. 1, pp. 3-7 (1995).				
C24	Stephens, S., et al., "A Longitudinal Study of γ-Interferon Production by Peripheral Blood Mononuclear Cells from Breast- and Bottle-Fed Infants," Clin. Exp. Immunol., vol. 65, pp. 396-400 (1986).				
C25	Stewart, R., et al., "Glutamate Accumulation By Human Gliomas and Meningiomas in Tissue Culture," Brain Research, vol. 118, no. 3, pp. 441-452 (1976).				
C26	Stoop, J., et al., "Identification of Malignant Cells in Serous Effusions Using a Panel of Monoclonal Antibodies Ber-EP4, MCA-b-12 and EMA," Cytopathology, vol. 3, pp. 297-302 (1992).				
C27	Wiseman, I., "A Modification of Hepatest, using the Terasaki Plate, for the Detection of Hb _S Ag in Blood Donors," J Clin Pathol, vol. 29, no. 3, pp. 264-266 (1976).				
C28	International Search Report for PCT/US01/32540 dated April 18, 2002.				
C29	International Search Report for PCT/US97/11595 dated August 17, 1998.				
C30	International Search Report for EP 97 93 3267 dated May 3, 2002.				
		RECEIVED			
	FEB 1 2003				
	AND OF PATE				
EXAMINER	RGITOMER D.	AND INTERFERENCES			